All Stories

  1. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment

    Article • World Journal of Diabetes, February 2022, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Michalis Kostapanos

  2. Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia

    Article • Journal of Cardiovascular Development and Disease, January 2022, MDPI AG

    Michalis Kostapanos

  3. Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, pa...

    Article • BMJ Open, April 2021, BMJ

    Michalis Kostapanos

  4. Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

    Article • European Journal of Drug Metabolism and Pharmacokinetics, November 2020, Springer Science + Business Media

    Michalis Kostapanos

  5. muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial

    Article • Trials, July 2020, Springer Science + Business Media

    Michalis Kostapanos

  6. Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial

    Article • Trials, July 2020, Springer Science + Business Media

    Michalis Kostapanos

  7. Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?

    Article • Expert Opinion on Pharmacotherapy, November 2019, Taylor & Francis

    Michalis Kostapanos

  8. Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including Registries

    Article • Current Pharmaceutical Design, January 2019, Bentham Science Publishers

    Evangelos Liberopoulos, Moses Elisaf, Michalis Kostapanos, Mat;ilda Florentin

  9. Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial

    Article • BMJ Open, September 2018, BMJ

    Michalis Kostapanos

  10. Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

    Article • Antiviral Therapy, May 2018, SAGE Publications

    Michalis Kostapanos

  11. Statins and mortality: the untold story

    Article • British Journal of Clinical Pharmacology, March 2017, Wiley

    Michalis Kostapanos

  12. Clinical relevance of central blood pressure - a critical review

    Article • VASA, November 2016, Hogrefe Publishing Group

    Michalis Kostapanos

  13. Statins and their increased risk of inducing diabetes

    Article • Expert Opinion on Drug Safety, October 2015, Informa Healthcare

    Michalis Kostapanos

  14. Effects of benchmarking on the quality of type 2 diabetes care: results of the OPTIMISE (Optimal Type 2 Diabetes Management Including Benchmarking and Standard Treatment) study in Greece

    Article • Therapeutic Advances in Endocrinology and Metabolism, July 2015, SAGE Publications

    Michalis Kostapanos

  15. Proton pump inhibitors and statins: a combination that favors ldl-c reduction?

    Article • Atherosclerosis, July 2015, Elsevier

    Michalis Kostapanos

  16. Variable effects of statins on glucose homeostasis parameters and their diabetogenic role

    Article • Diabetologia, May 2015, Springer Science + Business Media

    Michalis Kostapanos

  17. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic

    Article • Current Medical Research and Opinion, November 2014, Informa Healthcare

    Michalis Kostapanos

  18. Emerging drugs for hyperlipidaemia: an update

    Article • Expert Opinion on Emerging Drugs, October 2014, Informa Healthcare

    Michalis Kostapanos

  19. The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, September 2014, SAGE Publications

    Michalis Kostapanos

  20. The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose

    Article • Atherosclerosis, August 2014, Elsevier

    Michalis Kostapanos

  21. Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic

    Article • Angiology, May 2014, SAGE Publications

    Michalis Kostapanos

  22. Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases

    Article • Drug Safety, May 2014, Springer Science + Business Media

    Michalis Kostapanos

  23. Hemostatic Factors and the Metabolic Syndrome

    Article • Current Vascular Pharmacology, January 2014, Bentham Science Publishers

    Michalis Kostapanos

  24. High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship

    Article • World Journal of Experimental Medicine, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Michalis Kostapanos

  25. Pioglitazone and Cancer: Angel or Demon?

    Article • Current Pharmaceutical Design, June 2013, Bentham Science Publishers

    Michalis Kostapanos

  26. Colesevelam Plus Rosuvastatin 5 mg/Day Versus Rosuvastatin 10 mg/Day Alone on Markers of Insulin Resistance in Patients with Hypercholesterolemia and Impaired Fasting Glucose

    Article • Metabolic Syndrome and Related Disorders, June 2013, Mary Ann Liebert Inc

    Michalis Kostapanos

  27. Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias

    Article • Current Pharmaceutical Design, April 2013, Bentham Science Publishers

    Michalis Kostapanos

  28. Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)

    Article • Current Pharmaceutical Design, April 2013, Bentham Science Publishers

    Michalis Kostapanos

  29. Fenofibrate and the kidney: an overview

    Article • European Journal of Clinical Investigation, March 2013, Wiley

    Michalis Kostapanos

  30. Modelling eating practices in non-fatal acute coronary syndrome or stroke development: A case/case-control study

    Article • Nutrition Metabolism and Cardiovascular Diseases, March 2013, Elsevier

    Michalis Kostapanos

  31. Effect of Simvastatin/Ezetimibe 10/10 mg Versus Simvastatin 40 mg on Serum Vitamin D Levels

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, January 2013, SAGE Publications

    Michalis Kostapanos

  32. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease

    Article • World Journal of Hepatology, January 2013, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Michalis Kostapanos

  33. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity

    Article • Journal of Clinical Lipidology, January 2013, Elsevier

    Michalis Kostapanos

  34. Gender Differences in the Epidemiology, Clinical Presentation, Prevention, and Prognosis of Acute Coronary Syndromes

    Article • Angiology, December 2012, SAGE Publications

    Michalis Kostapanos

  35. Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?

    Article • Future Cardiology, November 2012, Future Medicine

    Michalis Kostapanos

  36. New-onset extremely low levels of high-density lipoprotein cholesterol

    Article • Journal of Clinical Lipidology, November 2012, Elsevier

    Michalis Kostapanos

  37. Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events

    Article • JAMA, September 2012, American Medical Association (AMA)

    Michalis Kostapanos

  38. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome

    Article • International Journal of Clinical Practice, August 2012, Hindawi Publishing Corporation

    Michalis Kostapanos

  39. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment

    Article • Current Medical Research and Opinion, August 2012, Taylor & Francis

    Michalis Kostapanos

  40. Ezetimibe – a new approach in hypercholesterolemia management

    Article • Pharmacological Reports, July 2012, Springer Science + Business Media

    Michalis Kostapanos

  41. Hypertriglyceridemia-induced acute pancreatitis: clinical considerations

    Article • Clinical Lipidology, June 2012, Taylor & Francis

    Michalis Kostapanos

  42. Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, April 2012, SAGE Publications

    Michalis Kostapanos

  43. Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]

    Article • Current Vascular Pharmacology, March 2012, Bentham Science Publishers

    Michalis Kostapanos

  44. Obstructive Sleep Apnea and Cardiovascular Risk

    Article • Angiology, February 2012, SAGE Publications

    Michalis Kostapanos

  45. Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease

    Article • Digestive Diseases and Sciences, February 2012, Springer Science + Business Media

    Michalis Kostapanos

  46. Therapeutic options for statin-intolerant patients

    Article • Current Medical Research and Opinion, January 2012, Informa Healthcare

    Michalis Kostapanos

  47. Letter to the Editor Obstructive sleep apnoea syndrome and cardiovascular risk

    Article • Archives of Medical Science, January 2012, Termedia Sp. z.o.o.

    Assistant Professor Paschalis Steiropoulos, Michalis Kostapanos

  48. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension

    Article • Journal of Human Hypertension, December 2011, Springer Science + Business Media

    Michalis Kostapanos

  49. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance

    Article • International Journal of Clinical Practice, October 2011, Hindawi Publishing Corporation

    Michalis Kostapanos

  50. Clopidogrel vs. Aspirin Treatment on Admission Improves 5-Year Survival After a First-ever Acute Ischemic Stroke. Data from the Athens Stroke Outcome Project

    Article • Archives of Medical Research, August 2011, Elsevier

    Michalis Kostapanos

  51. The association between Type D personality and the metabolic syndrome: a cross-sectional study in a University-based outpatient lipid clinic

    Article • BMC Research Notes, April 2011, Springer Science + Business Media

    Michalis Kostapanos

  52. The impact of the metabolic syndrome on health-related quality of life: a cross-sectional study in Greece

    Article • European Journal of Cardiovascular Nursing, March 2011, SAGE Publications

    Michalis Kostapanos

  53. Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress

    Article • Lipids, February 2011, Wiley

    Michalis Kostapanos

  54. JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses

    Article • World Journal of Cardiology, January 2011, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Michalis Kostapanos

  55. Apolipoprotein B-to-A1 Ratio as a Predictor of Acute Ischemic Nonembolic Stroke in Elderly Subjects

    Article • Journal of Stroke and Cerebrovascular Diseases, November 2010, Elsevier

    Michalis Kostapanos

  56. Do Statins Beneficially or Adversely Affect Glucose Homeostasis?

    Article • Current Vascular Pharmacology, September 2010, Bentham Science Publishers

    Michalis Kostapanos

  57. Do Statins Beneficially or Adversely Affect Glucose Homeostasis?

    Article • Current Vascular Pharmacology, June 2010, Bentham Science Publishers

    Michalis Kostapanos

  58. Current role of statins in the treatment of essential hypertension

    Article • Expert Opinion on Pharmacotherapy, May 2010, Informa Healthcare

    Michalis Kostapanos

  59. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective study

    Article • Clinical Therapeutics, March 2010, Elsevier

    Michalis Kostapanos

  60. Plasma triglyceride levels and body mass index values are the most important determinants of preβ-1 HDL concentrations in patients with various types of primary dyslipidemia

    Article • Atherosclerosis, February 2010, Elsevier

    Michalis Kostapanos

  61. Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia

    Article • American Journal of Cardiovascular Drugs, February 2010, Springer Science + Business Media

    Michalis Kostapanos

  62. Does intensive cholesterol lowering increase the risk of diabetes?

    Article • International Journal of Clinical Practice, December 2009, Hindawi Publishing Corporation

    Michalis Kostapanos

  63. Statin Pleiotropy Against Renal Injury

    Article • Journal of the CardioMetabolic Syndrome, December 2009, Wiley

    Michalis Kostapanos

  64. Association Between Serum γ-Glutamyltransferase and Acute Ischemic Nonembolic Stroke in Elderly Subjects

    Article • Archives of Medical Research, October 2009, Elsevier

    Michalis Kostapanos

  65. Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, September 2009, SAGE Publications

    Michalis Kostapanos

  66. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose

    Article • International Journal of Clinical Practice, September 2009, Hindawi Publishing Corporation

    Michalis Kostapanos

  67. Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, March 2009, SAGE Publications

    Michalis Kostapanos

  68. Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome

    Article • Journal of Clinical Lipidology, August 2008, Elsevier

    Michalis Kostapanos

  69. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia

    Article • European Journal of Pharmacology, August 2008, Elsevier

    Michalis Kostapanos

  70. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

    Article • Diabetes Obesity and Metabolism, June 2008, Wiley

    Michalis Kostapanos

  71. An Overview of the Extra-Lipid Effects of Rosuvastatin

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, May 2008, SAGE Publications

    Michalis Kostapanos

  72. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia

    Article • European Journal of Pharmacology, January 2008, Elsevier

    Michalis Kostapanos

  73. Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women

    Article • Diabetes/Metabolism Research and Reviews, January 2008, Wiley

    Michalis Kostapanos

  74. Dose-Dependent Effect of Rosuvastatin Treatment on Urinary Protein Excretion

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, December 2007, SAGE Publications

    Michalis Kostapanos

  75. Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome

    Article • Journal of the Renin-Angiotensin-Aldosterone System, December 2007, Hindawi Publishing Corporation

    Michalis Kostapanos

  76. Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A 2

    Article • Arteriosclerosis Thrombosis and Vascular Biology, October 2007, Wolters Kluwer Health

    Michalis Kostapanos

  77. Do statins have an antiarrhythmic activity?

    Article • Cardiovascular Research, July 2007, European Society of Cardiology

    Michalis Kostapanos

  78. A 12-Week, Prospective, Open-Label Analysis of the Effect of Rosuvastatin on Triglyceride-Rich Lipoprotein Metabolism in Patients with Primary Dyslipidemia

    Article • Clinical Therapeutics, July 2007, Elsevier

    Michalis Kostapanos

  79. Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects

    Article • International Journal of Clinical Practice, March 2007, Hindawi Publishing Corporation

    Michalis Kostapanos

  80. Rosuvastatin Increases α-1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia

    Article • The Journal of Clinical Pharmacology, November 2006, Wiley

    Michalis Kostapanos

  81. Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)

    Article • Current Medical Research and Opinion, May 2006, Informa Healthcare

    Michalis Kostapanos